<DOC>
	<DOCNO>NCT02669862</DOCNO>
	<brief_summary>This randomize , double-blind , vehicle-controlled , parallel-group study 3 treatment group .</brief_summary>
	<brief_title>A Study A-101 Solution Subjects With Common Warts .</brief_title>
	<detailed_description>This randomize , double-blind , vehicle-controlled , parallel-group study 3 treatment group . During Visit 1 , Investigator identify 1 eligible common wart trunk extremity subject . The wart treat maximum 8 time 1 week interval study .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject least 18 year age 2 . Subject clinical diagnosis common warts 3 . Subject 1 appropriate Target Wart define , trunk extremity : Have long axis 3mm 10mm Have thickness ≤3mm Be discrete lesion Be , center circular cutout provide template , common wart present Not periungual , subungual , genital anal Not cover hair , Investigator 's opinion , would interfere study medication treatment study evaluation Not area may occlude ( clothing , footwear within skin fold ) . 4 . The Target Wart PWA ≥2 5 . If subject woman childbearing potential , negative urine pregnancy test agree use approve effective method birth control duration study 6 . Subject nonpregnant nonlactating 7 . Subject good general health free know disease state physical condition , Investigator 's opinion , might put subject undue risk study participation interfere study conduct evaluation 8 . Subject willing able follow study instruction attend study visit 9 . Subject able comprehend willing sign Informed Consent Form . 1 . Subject clinically atypical wart trunk extremities 2 . Subject immune compromise ( due chemotherapy , systemic steroid , genetic immunodeficiency , transplant status , etc . ) 3 . Subject history Human Immunodeficiency Virus ( HIV ) infection 4 . Subject Human Papilloma Virus ( HPV ) vaccine within 1 year prior enrollment 5 . Subject use follow intralesional therapy within specified period prior enrollment Target Wart : Immunotherapy ( Candida antigen , mumps antigen , Trichophyton antigen ) ; Antimetabolite therapy ( bleomycin , 5fluorouracil ) 6 . Subject use follow systemic therapy within specified period prior enrollment : Immunomodulatory/immunosuppressant therapy ( e.g. , etanercept , alefacept , infliximab ) ; Glucocorticosteroids ( inhale intranasal steroid permit ) ; 7 . Subject use follow topical therapy within specified period prior enrollment , proximity Target Wart , Investigator 's opinion , might put subject undue risk study participation interfere study conduct evaluation : LASER ( pulseddye laser ) , light ( intense pulse light , photodynamic therapy , energy base therapy ) ; Immunotherapy ( imiquimod , squaric acid dibutyl ester , etc . ) ; Antimetabolite therapy ( 5fluorouracil ) ; Retinoids ; Liquid nitrogen , electrodesiccation , curettage ; Overthecounter wart therapies 8 . Subject follow within specified period prior enrollment , proximity target lesion , Investigator 's opinion , might put subject undue risk study participation interfere study conduct evaluation : A cutaneous malignancy ; A premalignancy ( actinic keratosis ) 9 . Subject history sensitivity ingredient study medication 10 . Subject current skin disease ( psoriasis , atopic dermatitis , eczema , sun damage , etc . ) , skin condition ( sunburn , open wound ) disease condition ( uncontrolled diabetes ) , Investigator 's opinion , might put subject undue risk study participation interfere study conduct evaluation 11 . Subject participate investigational drug trial administration investigational study medication occur within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>